IN2014DN05865A - - Google Patents
Info
- Publication number
- IN2014DN05865A IN2014DN05865A IN5865DEN2014A IN2014DN05865A IN 2014DN05865 A IN2014DN05865 A IN 2014DN05865A IN 5865DEN2014 A IN5865DEN2014 A IN 5865DEN2014A IN 2014DN05865 A IN2014DN05865 A IN 2014DN05865A
- Authority
- IN
- India
- Prior art keywords
- infection
- mycobacterium
- antigens
- prevention
- treatment
- Prior art date
Links
- 241000186359 Mycobacterium Species 0.000 abstract 3
- 239000000427 antigen Substances 0.000 abstract 3
- 102000036639 antigens Human genes 0.000 abstract 3
- 108091007433 antigens Proteins 0.000 abstract 3
- 208000015181 infectious disease Diseases 0.000 abstract 3
- 230000002265 prevention Effects 0.000 abstract 2
- 208000031998 Mycobacterium Infections Diseases 0.000 abstract 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 abstract 1
- 208000027531 mycobacterial infectious disease Diseases 0.000 abstract 1
- 230000037361 pathway Effects 0.000 abstract 1
- 229910021653 sulphate ion Inorganic materials 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/35—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Mycobacteriaceae (F)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
- C12N9/1241—Nucleotidyltransferases (2.7.7)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
- C12Y207/07—Nucleotidyltransferases (2.7.7)
- C12Y207/07004—Sulfate adenylyltransferase (2.7.7.4)
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Public Health (AREA)
- Pulmonology (AREA)
- Communicable Diseases (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161579166P | 2011-12-22 | 2011-12-22 | |
| PCT/AU2012/001569 WO2013091004A1 (en) | 2011-12-22 | 2012-12-20 | Prevention and treatment of mycobacterium infection |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2014DN05865A true IN2014DN05865A (enExample) | 2015-05-22 |
Family
ID=48667508
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN5865DEN2014 IN2014DN05865A (enExample) | 2011-12-22 | 2012-12-20 |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US9610337B2 (enExample) |
| EP (1) | EP2794885B1 (enExample) |
| CN (1) | CN104271744B (enExample) |
| AU (1) | AU2012357637B9 (enExample) |
| ES (1) | ES2655190T3 (enExample) |
| IN (1) | IN2014DN05865A (enExample) |
| WO (1) | WO2013091004A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105567660B (zh) * | 2016-01-08 | 2018-11-20 | 中国人民解放军第四军医大学 | 一种大肠杆菌重组表达结核分枝杆菌Rv2837c活性蛋白的方法及其应用 |
| WO2019147509A1 (en) * | 2018-01-26 | 2019-08-01 | The Regents Of The University Of California | Intranasal delivery of a cyclic-di-nucleotide adjuvanted vaccine for tuberculosis |
| MX2020011298A (es) * | 2018-04-26 | 2021-01-29 | Childrens Nat Medical Ct | Composiciones de antígeno micobacteriano y métodos de uso. |
| EP3797791A1 (en) * | 2019-09-26 | 2021-03-31 | Universidad De Zaragoza | Therapeutic efficacy by pulmonary delivery of live attenuated mycobacteria |
| WO2021243417A1 (en) * | 2020-06-05 | 2021-12-09 | Centenary Institute Of Cancer Medicine And Cell Biology | Immunogenic formulations |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR9608894A (pt) * | 1995-05-23 | 1999-12-07 | Univ California | Produtos extracelulares abundantes e processos para suas producões e usos |
| WO2002004018A2 (en) * | 2000-07-10 | 2002-01-17 | Colorado State University Research Foundation | Mid-life vaccine and methods for boosting anti-mycobacterial immunity |
| US6858213B2 (en) * | 2001-04-20 | 2005-02-22 | The Regents Of The University Of California | Mycobacterial sulfation pathway proteins and methods of use thereof |
| US7074559B2 (en) * | 2002-03-06 | 2006-07-11 | Refents of the University of Minnesota | Mycobacterial diagnostics |
| US20100015171A1 (en) * | 2008-07-15 | 2010-01-21 | Statens Serum Institute | Vaccines comprising tb 10.4 |
| EP2355798A1 (en) * | 2008-11-12 | 2011-08-17 | Statens Serum Institut | Modified cationic liposome adjuvans |
-
2012
- 2012-12-20 ES ES12859440.5T patent/ES2655190T3/es active Active
- 2012-12-20 US US14/367,854 patent/US9610337B2/en not_active Expired - Fee Related
- 2012-12-20 EP EP12859440.5A patent/EP2794885B1/en active Active
- 2012-12-20 CN CN201280070011.6A patent/CN104271744B/zh not_active Expired - Fee Related
- 2012-12-20 AU AU2012357637A patent/AU2012357637B9/en not_active Ceased
- 2012-12-20 IN IN5865DEN2014 patent/IN2014DN05865A/en unknown
- 2012-12-20 WO PCT/AU2012/001569 patent/WO2013091004A1/en not_active Ceased
-
2017
- 2017-02-28 US US15/445,697 patent/US9931391B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| EP2794885B1 (en) | 2017-10-04 |
| CN104271744B (zh) | 2017-06-06 |
| US9610337B2 (en) | 2017-04-04 |
| AU2012357637B9 (en) | 2017-10-19 |
| US9931391B2 (en) | 2018-04-03 |
| ES2655190T3 (es) | 2018-02-19 |
| US20170173137A1 (en) | 2017-06-22 |
| AU2012357637A1 (en) | 2014-07-17 |
| EP2794885A4 (en) | 2015-07-22 |
| US20160022795A1 (en) | 2016-01-28 |
| WO2013091004A1 (en) | 2013-06-27 |
| CN104271744A (zh) | 2015-01-07 |
| EP2794885A1 (en) | 2014-10-29 |
| AU2012357637B2 (en) | 2017-09-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MY192848A (en) | Compositions and methods for the treatment of hemoglobinopathies | |
| BR112012022755A2 (pt) | composição com bactérias probióticas para uso no tratamento de distúrbios imunológicos | |
| IN2014CN03555A (enExample) | ||
| NZ708928A (en) | Mannose derivatives for treating bacterial infections | |
| MX359327B (es) | Composiciones y sus usos para tratar y prevenir la enfermedad de huntington. | |
| WO2015003816A3 (en) | Cystobactamides | |
| PH12015502216A1 (en) | Compositions and methods for improving the health of aquatic animals | |
| PH12013502135A1 (en) | Antimicrobial compounds and methods of making and using the same | |
| IN2012DN00624A (enExample) | ||
| GB201103062D0 (en) | Method | |
| SG10201808940WA (en) | Nox inhibitor and nfкb inhibitor containing methoxyflavone | |
| IN2015DN00438A (enExample) | ||
| MX2021011946A (es) | Composiciones de inh-c1 y metodos para la prevencion y el tratamiento de trastornos asociados con la deficiencia del inhibidor de c1 esterasa. | |
| MX2015015416A (es) | Inhibidores de acetil-coa carboxilasa (acc) y usos de los mismos. | |
| MY195743A (en) | Isoxazole Hydroxamic Acid Compounds as LPXC Inhibitors | |
| SG10201807059QA (en) | Agents for influenza neutralization | |
| SG10201900541QA (en) | Derivatives of xanthone compounds | |
| IN2014DN05865A (enExample) | ||
| MX348397B (es) | Uso de extractos de filipendula para el tratamiento y profilaxis de dolor crónico. | |
| AU2015308650A8 (en) | Process for enhancing the viable counts of lactic acid bacteria and useful compositions thereof | |
| MX2015011198A (es) | Compuestos antivirales. | |
| UA115305C2 (uk) | Композиції hyr1-похідних і способи лікування ними | |
| IN2014DN00254A (enExample) | ||
| MX347541B (es) | Analogos de acido sialico. | |
| TW201611845A (en) | Treatment and functional cure of HIV infection by monoclonal antibodies to CD4 mediating competitive HIV entry inhibition |